Colchicine
Treatment for Gout
Typical Dosage: Acute: 1.2 mg then 0.6 mg 1 hour later; Prophylaxis: 0.6 mg once or twice daily
Effectiveness
83%
Safety Score
60%
Clinical Trials
44
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Acute: 1.2 mg then 0.6 mg 1 hour later; Prophylaxis: 0.6 mg once or twice daily
Time to Effect
12-24 hours (acute), immediate (prophylaxis effect)
Treatment Duration
1-3 days (acute), 3-6 months (prophylaxis)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
7(Treat 7 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150
Monitoring:$50
Side Effect Mgmt:$20
Total Annual:$220
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$8,000/QALY
QALYs Gained
0.01
Outcome-Based Costs
Cost per Responder
$259
Colchicine Outcomes
for Gout
Efficacy Outcomes
Overall Effectiveness
+83%
Response Rate
+85%
Common Side Effects
Diarrhea
+15%
Nausea, vomiting, abdominal pain
+7%
Sources:
Active Clinical Trials
2 active trials recruiting for Colchicine in Gout
Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.
NCT05690204ACTIVE NOT RECRUITINGPHASE2
87 participants
INTERVENTIONAL
Sacramento, United States +15 more
Started: Dec 12, 2022
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
NCT04875702RECRUITINGPHASE4
650 participants
INTERVENTIONAL
South Birmingham, United States +6 more
Started: Feb 22, 2024
Completed Clinical Trials
15 completed trials for Colchicine in Gout
Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout
NCT02330796COMPLETEDPHASE2
66 participants
INTERVENTIONAL
San Roman, United States +2 more
Started: Apr 1, 2015
Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol
NCT01451645COMPLETEDPHASE4
82 participants
INTERVENTIONAL
Alabaster, United States +36 more
Started: Oct 1, 2011
Apolipoprotein CIII Reduction Via Colchicine
NCT02083510COMPLETEDEARLY_PHASE1
5 participants
INTERVENTIONAL
La Jolla, United States
Started: Feb 1, 2014
The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout
NCT03131583COMPLETEDPHASE1
15 participants
INTERVENTIONAL
Suzhou, China
Started: Feb 17, 2017
Colchicine Or Naproxen Treatment for ACute gouT
NCT01994226COMPLETEDPHASE4
399 participants
INTERVENTIONAL
Stoke-on-Trent, United Kingdom
Started: Jan 1, 2014
MPC-004 for the Treatment of an Acute Gout Flare
NCT00506883COMPLETEDPHASE3
185 participants
INTERVENTIONAL
Birmingham, United States +82 more
Started: Apr 1, 2007
A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)
NCT00819585COMPLETEDPHASE2
432 participants
INTERVENTIONAL
Huntington Beach, United States +88 more
Started: Dec 1, 2008
Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare
NCT05936268COMPLETEDPHASE2
106 participants
INTERVENTIONAL
Shanghai, China
Started: Jul 21, 2023
Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients
NCT01416402COMPLETEDPHASE2
27 participants
INTERVENTIONAL
Overland Park, United States
Started: Aug 1, 2011
Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels
NCT02060552COMPLETEDPHASE4
96 participants
INTERVENTIONAL
Wuhan, China
Started: Jan 1, 2013
Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients
NCT01399008COMPLETEDPHASE2
100 participants
INTERVENTIONAL
Lincoln, United States +23 more
Started: Jun 1, 2011
Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS)
NCT04130204COMPLETEDPHASE2
284 participants
INTERVENTIONAL
Poway, United States
Started: Feb 12, 2020
An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.
NCT01112982COMPLETEDPHASE4
74 participants
INTERVENTIONAL
Tampa, United States
Started: May 1, 2010
A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202)
NCT05936281COMPLETEDPHASE2
165 participants
INTERVENTIONAL
Shanghai, China
Started: Jul 20, 2023
Pharmacokinetic Study of an Acute Gout Regimen
NCT01017042COMPLETEDPHASE1
13 participants
INTERVENTIONAL
Fargo, United States
Started: Sep 1, 2007
Showing 20 of 44 total trials